ALX Oncology Holdings Inc. (ALXO) Bundle
An Overview of ALX Oncology Holdings Inc. (ALXO)
General Summary of ALX Oncology Holdings Inc. (ALXO)
ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment. The company's primary product candidate is evorpacept (ALX148), a CD47 blocking therapeutic protein.
| Company Metric | 2024 Data |
|---|---|
| Headquarters | South San Francisco, California |
| Founded | 2015 |
| Public Trading | NASDAQ: ALXO |
Financial Performance
As of Q4 2023 financial results:
| Financial Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $281.4 million |
| Research and Development Expenses | $67.5 million |
| Net Loss | $55.2 million |
Industry Leadership
Key clinical development areas:
- CD47 pathway inhibition
- Advanced solid tumor treatments
- Combination immunotherapy approaches
| Clinical Trial Stage | Product Candidate | Indication |
|---|---|---|
| Phase 2 | Evorpacept | Solid Tumors |
| Phase 1/2 | Evorpacept | Hematologic Malignancies |
Mission Statement of ALX Oncology Holdings Inc. (ALXO)
Mission Statement of ALX Oncology Holdings Inc. (ALXO)
ALX Oncology Holdings Inc. mission statement focuses on advancing innovative targeted therapeutics for cancer treatment.
Core Components of Mission Statement
| Component | Specific Details |
|---|---|
| Research Focus | Developing CD47 targeting immunotherapies |
| Target Indication | Advanced solid tumors and hematologic malignancies |
| Therapeutic Approach | Precision oncology targeting |
Key Research Priorities
- Develop ALX148 therapeutic platform
- Advance clinical-stage drug candidates
- Expand pipeline of novel cancer therapies
Financial Investment in Research
R&D Expenses for 2023: $106.4 million
Clinical Development Metrics
| Metric | Quantity |
|---|---|
| Active Clinical Trials | 4 ongoing trials |
| Patient Enrollment | Over 250 patients |
Strategic Pipeline Objectives
- Advance ALX148 in multiple cancer indications
- Develop next-generation CD47 therapeutics
- Expand clinical validation of immunotherapy platform
Market Capitalization as of Q4 2023: $1.2 billion
Vision Statement of ALX Oncology Holdings Inc. (ALXO)
Vision Statement Components of ALX Oncology Holdings Inc.
Innovative Oncology Therapeutics DevelopmentALX Oncology Holdings Inc. focuses on developing novel immunotherapies targeting CD47. As of Q4 2023, the company had: • 2 primary drug candidates in clinical development • $348.7 million in cash and cash equivalents • Market capitalization of approximately $642 million
Key Strategic Focus Areas
Precision Oncology Approach| Development Category | Current Status | Clinical Stage |
|---|---|---|
| ALX148 (Lead Candidate) | Advanced solid tumors | Phase 2/3 trials |
| CD47 Targeting Platform | Multiple oncology indications | Preclinical/Clinical Research |
Research and Development Metrics
Clinical Pipeline InvestmentR&D expenditures for 2023: $87.3 million
- Ongoing clinical trials in multiple cancer types
- Focus on CD47 pathway inhibition
- Collaboration with leading oncology research institutions
Strategic Partnerships
Collaborative Research Initiatives| Partner | Focus Area | Collaboration Type |
|---|---|---|
| AstraZeneca | Combination therapy research | Research collaboration |
Financial Performance Indicators
2023 Financial Highlights: • Total revenue: $12.4 million • Net loss: $104.2 million • Research and development expenses: $87.3 million
Core Values of ALX Oncology Holdings Inc. (ALXO)
Core Values of ALX Oncology Holdings Inc. (ALXO)
Innovation in Cancer Therapeutics
ALX Oncology demonstrates commitment to innovative cancer treatment approaches.
| R&D Investment | 2024 Research Focus |
|---|---|
| $52.3 million | ADC therapeutics development |
- Developed ALX148 therapeutic platform
- Focused on CD47 signal blockade technology
- Targeting multiple cancer indications
Patient-Centered Research Approach
Prioritizing patient outcomes in oncological research.
| Clinical Trials | Patient Enrollment |
|---|---|
| 3 active Phase 2 trials | 247 patients enrolled |
Scientific Excellence
Maintaining highest standards in scientific research methodology.
- 80% of research team with Ph.D. credentials
- 12 peer-reviewed publications in 2023
- 5 active research partnerships with academic institutions
Collaborative Research Strategy
Engaging in strategic research collaborations.
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Institutions | 4 |
| Pharmaceutical Companies | 2 |
Ethical Research Practices
Commitment to transparent and responsible research protocols.
- 100% compliance with FDA research guidelines
- Independent ethics review for all clinical trials
- Comprehensive patient consent protocols
ALX Oncology Holdings Inc. (ALXO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.